FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Cannabinoids

  • Home
  •  | 
  • Tag Archives: "Cannabinoids"

CLS Holdings USA, Inc. Announces up to US$40 Million Brokered Private Placement

CLS Holdings USA, Inc. Announces up to US$40 Million Brokered Private Placement
LAS VEGAS, Oct. 08, 2018 (GLOBE NEWSWIRE) -- CLS Holdings USA, Inc. (OTCQB: CLSH) ("CLS" or the "Company") today announced that it has entered into an agreement with a Canadian agent (the "Agent"), whereby the Agent will assist the Company in selling on a commercially reasonable efforts private placement basis, up to US$40 million aggregate principal amount of senior unsecured debentures (“Debentures”) with an issue price of US$1,000 per Debenture, convertible into units of the Company (the “Units”) at the option of the holder at a conversion price of US$0.80 per Unit (the “Conversion Price”) at any time prior to the close of business on the earlier of: (i) the last business day immediately preceding the maturity date of the Debentures, being the date that is three (3) years from the closing date of the Offering (the “Closing Date”), and (ii) the date fixed for redemption (as set out in the Debentures (the “Offering”).
Read more

InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids

InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with Cannabinoids
Sept. 25, 2018 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has filed a Patent Cooperation Treaty ("PCT") application pertaining to the Company's INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, which is an important step in protecting the Company's intellectual and commercial property. The patent application, entitled "Methods and Composition for the Treatment of Pain with Cannabinoids" is designed to provide protection of the Company's INM-405 program in over 150 different countries including the United States and claims a priority date from September 22, 2017(PCT/CA202018/051194).
Read more

Relevium’s Biocannabix Subsidiary Signs Lease Agreement for Its ACMPR Facility

Relevium’s Biocannabix Subsidiary Signs Lease Agreement for Its ACMPR Facility MONTREAL, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:  “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company’s wholly owned subsidiary Biocannabix (“BCX”) has signed a lease agreement for the company’s anticipated 93,000 SQ. FT., vertically integrated facility located within…
Read more